This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

J&J Prostate Cancer Drug Scores Big Win, Hurts Dendreon, Helps Medivation

Second update with new information on the Zytiga study plus other background.

RARITAN, N.J. ( TheStreet) -- Johnson & Johnson's (JNJ) prostate cancer drug Zytiga prolonged the lives of patients with less advanced disease, according to results of a late-stage study announced Thursday.

Zytiga, a pill, is now in line to treat the same prostate cancer patients targeted by Dendreon (DNDN) with its Provenge immunotherapy. Dendreon shares fell 79 cents or 7% to $10.12 in Thursday trading on fears that Zytiga competition may further erode already-underperforming Provenge sales. Dendreon was down more sharply earlier Thursday but has rebounded because Zytiga's survival benefit in the study was not statistically significant.

Meantime, Medivation (MDVN) shares jumped $11.81, or 18% to $76 because its prostate cancer drug MDV3100 is a close cousin to Zytiga. Medivation is also conducting a late-stage study of MDV3100 in the same population of prostate cancer patients.

J&J shares are up 1% to $64.98.

In the J&J study, patients with prostate cancer who had not yet received chemotherapy were treated with Zytiga plus the steroid prednisone or a placebo plus prednisone.

An independent data monitoring panel stopped the study early based on findings which showed the Zytiga therapy significantly delayed the growth of prostate cancer and helped patients live longer compared to placebo. All patients in the study will now be offered Zytiga treatment, according to J&J.

The Zytiga trial was designed with co-primary endpoints of progression-free survival (PFS) and overall survival. The PFS benefit was statistically significant in favor of Zytiga while the drug showed a "strong trend" in prolonging survival that did not meet statistical significance," said J&J spokeswoman Kellie McLaughlin.

The independent data monitors "stopped the trial based on the totality of the data they saw," said McLauglin, which included statistically significant benefit on all secondary endpoints.

J&J plans to submit the Zytiga trial for presentation at an upcoming medical meeting, which could be the American Society of Clinical Oncology (ASCO) annual meeting in June.

Zytiga was first approved in 2011 as a treatment for prostate cancer patients who have previously been treated with chemotherapy. Thursday's results open a much larger commercial opportunity for J&J because if approved, Zytiga will become a treatment option for men with less advanced prostate cancer.

J&J has not disclosed the extent to which Zytiga prolongs survival in pre-chemo prostate cancer patients, but if the convenient twice-daily pill works equally or better than Provenge, Dendreon could face further difficulties. Determining the real survival benefit of Zytiga could be confounded by the trial stopping early.

Provenge is a cancer vaccine custom made for each patient and requires three infusions over the course of one month. Reimbursement issues and wavering demand for Provenge have slowed Dendreon's launch efforts, so a new drug or two entering as a direct competitor won't help.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,074.24 -98.44 -0.57%
S&P 500 1,985.76 -8.53 -0.43%
NASDAQ 4,513.1740 -14.5150 -0.32%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs